Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the change in patient-reported treatment
satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care,
using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for
Medication (TSQM-9).